Narang Mohit, Penner John A, Williams Dan
Michigan State University, Department of Medicine, Division of Hematology/Oncology, East Lansing, Michigan 48824, USA.
Am J Hematol. 2003 Dec;74(4):263-7. doi: 10.1002/ajh.10413.
"Refractory" autoimmune thrombocytopenia represents a life-threatening condition, having failed to respond to a variety of therapeutic measures. We report a series of cases, all failing splenectomy and multiple therapeutic programs, including, in two patients, marrow transplant. Five of the six cases reported responded to a recombinant antibody to the lymphocyte membrane antigen CD20 (rituximab), an agent commonly employed in the treatment of non-Hodgkin's lymphoma. Our experiences over a period of 4 years are documented. The results support the use of this product, rituximab, in the treatment of patients with autoimmune thrombocytopenia who have not attained a hemostatically effective platelet count following splenectomy and require a continuing therapeutic management program.
“难治性”自身免疫性血小板减少症是一种危及生命的疾病，对多种治疗措施均无反应。我们报告了一系列病例，所有病例均对脾切除术和多种治疗方案无效，其中两例还接受了骨髓移植。报告的6例病例中有5例对针对淋巴细胞膜抗原CD20的重组抗体（利妥昔单抗）有反应，该药物常用于治疗非霍奇金淋巴瘤。记录了我们4年期间的经验。结果支持使用利妥昔单抗这种产品来治疗自身免疫性血小板减少症患者，这些患者在脾切除术后血小板计数未达到止血有效水平且需要持续的治疗管理方案。
